Does MS grey matter atrophy progress faster in regions with more damage in connected white matter? - Rate of GM atrophy in MS

Vrije Universiteit Medisch Centrum0 个研究点目标入组 55 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•Patient group:
•1. Minimum age 18 years
•2. Clinical definite relapsing remitting MS for < 5 years
•3. Either receiving no treatment , or receiving first line treatment for at least 6 months
•4. Expanded Disability Status Score (EDSS) * 5.0
•5. Written informed consent ;Control group:
•1. Minimum age 18 years
•2. Written informed consent

•1. Past or current clinical relevant non-MS neurological or psychiatric disorder(s)
•2. Past or current clinical relevant (auto)immune disorder(s)
•3. Treatment with first line therapy for less than 6 months
•4. Treatment with second line therapy
•5. Relapse and/or steroid treatment in past 3 months
•6. Pregnancy
•7. MRI incompatibility, e.g. metal objects in or around the body, claustrophobia or inability to lie still in the scanner

发起方